Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment

Core Viewpoint - Edesa Biotech, Inc. is advancing its Phase 2 clinical study of EB06 for moderate-to-severe nonsegmental vitiligo, with enrollment expected to begin mid-2026, following the selection of JSS Medical Research as its clinical research organization [1][2][3] Company Overview - Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for immuno-inflammatory diseases, with a pipeline that includes EB06 for vitiligo and other assets for allergic contact dermatitis and respiratory conditions [7][8] Clinical Study Details - The Phase 2 study will assess the safety and efficacy of EB06 compared to placebo in adults with non-segmental vitiligo, involving intravenous infusions during the treatment period followed by a follow-up [4] - Site activations and patient recruitment for the clinical trial are anticipated to start in mid-2026, with initial sites located in Canada [2] Drug Mechanism and Background - EB06 is a monoclonal antibody targeting chemokine ligand 10 (CXCL10), which is implicated in the autoimmune response in vitiligo by promoting the trafficking of anti-melanocytic T-cells and inducing melanocyte apoptosis [5][6] - Preclinical studies have shown that EB06 can prevent and reverse depigmentation, demonstrating pharmacodynamic activity necessary to address the immune dysfunction associated with vitiligo [5] Vitiligo Overview - Vitiligo is a chronic autoimmune condition affecting 0.5% to 2% of the global population, characterized by unpredictable loss of skin pigmentation, often beginning before the age of 20 [6]